SC
PFE icon

Stolper & Co’s Pfizer PFE Stock Holding History

Stolper & Co’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.85M Buy
64,894
+1,283
+2% +$34.1K 0.48% 58
2026
Q2 		$1.53M Buy
63,611
+30,553
+92% +$799K 0.4% 59
2026
Q1 		$531K Sell
33,058
-28,240
-46% -$752K 0.15% 79
2025
Q4 		$1.53M Buy
61,298
+2,651
+5% +$66.9K 0.45% 57
2025
Q3 		$1.49M Buy
58,647
+3,170
+6% +$78.2K 0.45% 57
2025
Q2 		$1.34M Buy
55,477
+3,888
+8% +$90.7K 0.44% 58
2025
Q1 		$1.31M Buy
51,589
+1,604
+3% +$42K 0.43% 58
2024
Q4 		$1.33M Buy
49,985
+113
+0.2% +$3.06K 0.44% 57
2024
Q3 		$1.44M Sell
49,872
-318
-0.6% -$9.28K 0.47% 58
2024
Q2 		$1.4M Buy
50,190
+1,841
+4% +$50.7K 0.49% 57
2024
Q1 		$1.34M Buy
48,349
+4,036
+9% +$112K 0.48% 57
2023
Q4 		$1.28M Sell
44,313
-1,807
-4% -$54.6K 0.51% 55
2023
Q3 		$1.53M Buy
46,120
+1,167
+3% +$41.3K 0.66% 50
2023
Q2 		$1.65M Buy
44,953
+234
+0.5% +$9.11K 0.69% 47
2023
Q1 		$1.82M Buy
44,719
+620
+1% +$26.8K 0.78% 39
2022
Q4 		$2.26M Sell
44,099
-7,237
-14% -$347K 0.99% 31
2022
Q3 		$2.25M Buy
51,336
+2,475
+5% +$120K 1.11% 32
2022
Q2 		$2.56M Buy
48,861
+1,668
+4% +$85K 1.2% 30
2022
Q1 		$2.44M Buy
47,193
+1,562
+3% +$81K 1.04% 31
2021
Q4 		$2.7M Buy
45,631
+430
+1% +$21.3K 1.2% 27
2021
Q3 		$1.94M Buy
45,201
+959
+2% +$42.5K 0.93% 33
2021
Q2 		$1.73M Buy
44,242
+762
+2% +$29.6K 0.82% 37
2021
Q1 		$1.58M Buy
43,480
+605
+1% +$21.5K 0.81% 40
2020
Q4 		$1.58M Sell
42,875
-1,296
-3% -$47.5K 0.89% 38
2020
Q3 		$1.54M Sell
44,171
-4,020
-8% -$141K 0.99% 33
2020
Q2 		$1.5M Sell
48,191
-3,220
-6% -$109K 0.98% 36
2020
Q1 		$1.59M Buy
+51,411
New +$1.75M 1.14% 34

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Willis Investment Counsel
Willis Investment Counsel Gainesville, Georgia $1.97B AUM 25.29% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Stolper & Co's PFE Position: Q3 2026 in Review

Stolper & Co increased its Pfizer (PFE) stake by 2% in Q3 2026, buying an estimated $34.1K and bringing the position to 64,894 shares worth $1.85M. The position accounts for 0.48% of the portfolio, ranked #58.

Stolper & Co first reported a position in PFE in Q1 2020 and has held it in 27 quarters since. The position peaked at $2.7M in Q4 2021. 646 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Stolper & Co held 64,894 shares of Pfizer worth $1.85M as of Q3 2026.
  • Stolper & Co bought 1,283 Pfizer shares in Q3 2026, an estimated $34.1K.
  • Pfizer made up 0.48% of Stolper & Co's portfolio in Q3 2026, its #58 holding.
  • Stolper & Co first reported a position in Pfizer in Q1 2020 and has held it in 27 quarters since.
  • Stolper & Co's Pfizer position peaked at $2.7M in Q4 2021.
  • 646 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Stolper & Co's 13F filing for Q3 2026, filed 13 Oct 2026.